Nova Publishers
My Account Nova Publishers Shopping Cart
HomeBooksSeriesJournalsReference CollectionseBooksInformationSalesImprintsFor Authors
  Top » Catalog » Books » Medicine » Metabolic and Nutritional Disorders » My Account  |  Cart Contents  |  Checkout   
Quick Find
Use keywords to find the product you are looking for.
Advanced Search
What's New? more
Brain, Body, Cognition - A continuation of Functional Neurology, Rehabilitation and Ergonomics
Shopping Cart more
0 items
Shipping & Returns
Privacy Notice
Conditions of Use
Contact Us
01.Kynurenines in the Brain: From Experiments to Clinics
02.Trends in Exercise and Health Research
03.Psychiatric and Metabolic Disorders: Research Synthesis and Clinical Translation
04.Malnutrition in the 21st Century
05.Body Mass Index and Health
06.New Research on Morbid Obesity
07.Trends in Diabetes Mellitus Research
08.Neurochemistry of Metabolic Diseases: Lysosomal Storage Diseases, Phenylketonuria and Canavan Disease
09.Trends in Obesity Research
10.Global Dimensions of Childhood Obesity
Notifications more
NotificationsNotify me of updates to AMPK-S6K1 Signaling Pathway as a Target for Treating Hepatic Insulin Resistance
Tell A Friend
Tell someone you know about this product.
AMPK-S6K1 Signaling Pathway as a Target for Treating Hepatic Insulin Resistance
Retail Price: $69.00
10% Online Discount
You Pay:

Authors: Sang Geon Kim, Il, Je Cho, and Hee Yeon Kay ( Innovative Drug Research Center for Metabolic and Inflammatory Diseases, College of Pharmacy, Seoul National University, Seoul, Korea) 
Book Description:
Hepatic insulin resistance and altered insulin metabolism, as characterized by the desensitization of hepatic parenchymal cells to insulin, play a role in the pathogenesis of liver disease, particularly resulting in steatosis and steatohepatitis. By the same token, type II diabetic patients are at higher risk for developing liver diseases, including steatosis, hepatitis, cirrhosis, and hepatocellular carcinoma. On the other hand, established liver disease from any cause leads to glucose intolerance and peripheral insulin resistance systemically. The link between insulin resistance and liver pathology reviewed in this book suggests that insulin resistance is closely related with a variety of liver diseases. Recent evidence indicates that the AMP activating protein kinase (AMPK) in conjunction with p70 ribosomal S6 kinase 1 (S6K1) serves as a key signaling pathway regulating insulin-dependent physiological functions; thus, this pathway serves as a target for the therapy of diseases associated with insulin resistance. In this chapter, the regulatory role of the AMPK-S6K1 pathway is discussed in terms of enhancing insulin receptor signaling with insulin receptor substrate-1/2 and phosphatidylinositol phosphate kinase activity, which may contribute to preventing and/or treating insulin resistance in the liver.

We’ve partnered with Copyright Clearance Center to make it easy for you to request permissions to reuse Nova content.
For more information, click here or click the "Get Permission" button below to link directly to this book on Copyright Clearance Center's website.

Table of Contents:

1. Introduction, pp. 1-18

2. Clinical and preclinical drugs for the treatment of hepatic insulin resistance, pp. 19-28

Conclusion, pp. 29-30

Index, pp. 51

      Hepatology Research and Clinical Developments
   Binding: Softcover
   Pub. Date: 2011 - 2nd Quarter
   Pages: 6 x 9
   ISBN: 978-1-60876-693-2
   Status: AV
Status Code Description
AN Announcing
FM Formatting
PP Page Proofs
FP Final Production
EP Editorial Production
PR At Prepress
AP At Press
AV Available
Special Focus Titles
01.Violent Communication and Bullying in Early Childhood Education
02.Cultural Considerations in Intervention with Women and Children Exposed to Intimate Partner Violence
03.Chronic Disease and Disability: The Pediatric Lung
04.Fruit and Vegetable Consumption and Health: New Research
05.Fire and the Sword: Understanding the Impact and Challenge of Organized Islamism. Volume 2

Nova Science Publishers
© Copyright 2004 - 2020

AMPK-S6K1 Signaling Pathway as a Target for Treating Hepatic Insulin Resistance